Arbutus Biotech (ABUS) heads to a key March Moderna LNP patent trial as imdusiran HBV milestones drive value—get the latest ...

Based on key financial metrics such as the price-to-sales ratio, shareholder yield and the price-earnings ratio, the ...

When our body fights an infection, the immune system must quickly activate defenses and trigger a beneficial inflammatory ...

Small-molecule mitochondrial transcription factor A modulators stabilize mtDNA, preventing cytosolic escape and suppressing cGAS-STING interferon signaling, while improving bioenergetics and fibrosis ...

Kim Kardashian is pulling back the curtain on the beauty rituals behind her famously glossy hair and, bible, it’s pretty extreme. “I’ll do like the stem cell injections in my scalp,” dished Kim, ...

A Prescription Drug User Fee Act target date of August 30, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application ...

Add Yahoo as a preferred source to see more of our stories on Google. Kim Kardashian is pulling back the curtain on the beauty rituals behind her famously glossy hair and, bible, it's pretty extreme.

The U.S. Department of Health and Human Services will start a study on cellphone radiation, a department spokesman said on Thursday. “The FDA removed webpages with old conclusions about cell phone ...

Potential expansion of the BESREMi® (ropeginterferon alfa-2b-njft) product label to include adult patients with essential thrombocythemia (ET) BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA ...

PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles ...

EXCEED-ET Study Results Demonstrate Significant Efficacy, with Consistent Treatment Response Across the Overall Essential Thrombocythemia Population Results Extend Previously Reported Positive Phase 3 ...

ropeginterferon alfa-2b-njft recognized by National Comprehensive Cancer Network® (NCCN®) as recommended treatment option, listing it as a Category 1 preferred regimen for ET patients with inadequate ...